Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 18/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17583055 | 1.00 | IDH1 (0.37) | IDH1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL23559787 | 0.88 | OPRM1 (0.34) | IDH1OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL30543717 | 0.88 | OPRM1 (0.34) | IDH1OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL17586630 | 0.88 | OPRM1 (0.34) | IDH1OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL17582993 | 0.87 | ALK (0.36) | IDH1ALK | |
| SCHEMBL17583058 | 0.82 | IDH1 (0.34) | IDH1 | |
| SCHEMBL30659118 | 0.82 | EGFR (0.34) | IDH1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17582797 | 0.82 | EGFR (0.34) | IDH1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL25919584 | 0.77 | MAPT (0.35) | IDH1OPRM1OPRK1OGFRL1ALK | |
| SCHEMBL20110774 | 0.75 | ALK (0.35) | IDH1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289822-A2 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3572405-B9 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11834418-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-12-05 | — | — | US | disclosed |
| EP-3572405-B1 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20210188782-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2021-06-24 | — | — | US | disclosed |
| US-10906877-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC | 2021-02-02 | — | — | US | disclosed |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2020-02-27 | — | — | US | disclosed |
| EP-3572405-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Knopp Biosciences LLC (US) | 2019-11-27 | — | — | EP | disclosed |
| US-10385025-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3191457-B1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20180148419-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2018-05-31 | — | — | US | disclosed |
| US-9914708-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
| US-9481653-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160075663-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834418-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | IDH1 3023/4885OPRM1 1026/4885OPRD1 436/4885 |
| US-10385025-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | IDH1 3023/4885OPRM1 1026/4885OPRD1 436/4885 |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | IDH1 3023/4885OPRM1 1026/4885OPRD1 436/4885 |
| US-10906877-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | IDH1 3023/4885OPRM1 1026/4885OPRD1 436/4885 |
| US-20180148419-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | IDH1 3023/4885OPRM1 1026/4885OPRD1 436/4885 |
| US-20160075663-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | IDH1 3023/4885OPRM1 1026/4885OPRD1 436/4885 |
| US-20200062714-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | IDH1 3023/4885OPRM1 1026/4885OPRD1 436/4885 |
| US-20210188782-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | IDH1 3023/4885OPRM1 1026/4885OPRD1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.